Key facts
- ImmuONE’s last known valuation is $7.3M (Oct 2023).
- It has raised $3.4M; the latest was Later Stage VC ($760K) in Mar 2025.
- Notable investors include Innovate UK, Mercia Ventures, Midlands Engine Investment Fund, BioIndustry Association, ICURe — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for ImmuONE
- ·The full record, as it builds
Funding rounds
No funding rounds for ImmuONE are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ImmuONE
Operator of a biotech company intended for in vitro cell culture services for safety assessment. The company specializes in human alveolar macrophage responses, epithelial cell culture platforms, and testing services and also offers respiratory tissue models that closely resemble lung physiology to provide relevant, reliable, and reproducible results, enabling healthcare providers to innovate in vitro products and testing services for inhalation safety assessment using state-of-the-art techniques.
- Sector
- Healthcare
- HQ
- Stevenage, United Kingdom
- Founded
- 2019
- Employees
- 22
- Website
- immuone.com/
- Ownership
- Privately Held (backing)
ImmuONE doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ImmuONE shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ImmuONE in its N-PORT filings yet. We sweep new filings monthly.